Definium Therapeutics (DFTX) had a volatile Tuesday. Shares initially dipped on news of a proposed $500 million public offering, but quickly reversed course as investors zeroed in on something far more exciting: positive Phase 3 data for the company's depression drug.

The stock was trading at $38.24 as of publication, up 4.25% on the day. That's a nice bounce, but the technical picture suggests caution. The Relative Strength Index (RSI) is sitting at 84.57 — well into overbought territory. For context, anything above 70 is typically considered overbought, and 84.57 is the kind of number that makes traders nervous. The stock has gained 138.43% over the past 12 months, and its current price is significantly above its 20-day simple moving average of $24.34. That kind of extension often precedes a pullback.

The Drug That's Driving the Hype

The catalyst is DT120, an orally disintegrating tablet formulation of lysergide (yes, that lysergide) for major depressive disorder. On Monday, Definium announced topline results from the Emerge Phase 3 study, which evaluated a single 100 µg dose. The study hit its primary endpoint: a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the MADRS total score at week 6. MADRS is a standard scale for measuring depression severity, so this is a big deal.

The company plans to use proceeds from the $500 million offering to fund research and development, including preparation activities for potential commercialization of DT120 ODT, if approved.

Analysts Are Bullish — Very Bullish

Wall Street is on board. The stock carries a Buy rating with an average price target of $43.22, but several analysts have raised their forecasts significantly this week:

• Baird: Outperform, target raised to $57 (June 23)
• Needham: Buy, target raised to $50 (June 23)
• Leerink Partners: Outperform, target raised to $52 (June 22)
• Oppenheimer: Outperform, target raised to $60 (June 22)

Those targets imply substantial upside from current levels, but the overbought RSI and the dilutive effect of the public offering are risks to keep in mind. Definium is riding a wave of optimism, but in biotech, the tide can turn fast.